G. Adolf

发表

Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker

C. Klein, G. Bader, F. Solca, 2012, Journal of Pharmacology and Experimental Therapeutics.

Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression.

F M van den Berg, V J Wielenga, S T Pals, 1993, Cancer research.

Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44

P. Herrlich, K. Heider, G. Adolf, 1993, The Journal of experimental medicine.

Title: Target Binding Properties and Cellular Activity of Afatinib (bibw 2992), an Irreversible

C. Klein, G. Bader, F. Solca, 2012 .

Expression of CD44 isoforms on isolated bone marrow plasma cells and peripheral CD19+ B cells of patients with multiple myeloma and healthy individuals.

K. Heider, G. Adolf, H. Ludwig, 1999, Leukemia & lymphoma.

Expression of CD44 isoforms in human renal cell carcinomas

K. Zatloukal, K. Heider, G. Adolf, 1996, Virchows Archiv.

Expression of CD44 splice variants during lymphocyte activation and tumor progression.

P. Herrlich, K. Heider, A. Griffioen, 1994, Cell adhesion and communication.

Monoclonal antibodies to soluble human TNF receptor (TNF binding protein) enhance its ability to block TNF toxicity.

G. Adolf, B. Frühbeis, Günther R. Adolf, 1992, Cytokine.

Glucocorticoid hormones inhibit DNA synthesis and enhance Interferon production in a human lymphoid cell line

G. Adolf, P. Swetly, 1979, Nature.

Abstract A249: BI 853520, a potent and highly selective inhibitor of protein tyrosine kinase 2 (focal adhesion kinase), shows efficacy in multiple xenograft models of human cancer.

M. Schleicher, N. Kraut, P. Garin‐Chesa, 2011 .

Prognostic value of CD44 splice variant expression in ovarian cancer.

O. Dapunt, C. Marth, E. Müller-Holzner, 1995, Oncology.

Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys.

K. Heider, G. Adolf, E. Ostermann, 1995, European journal of cancer.

Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts

K. Heider, D. Kerjaschki, P. Garin‐Chesa, 2008, Clinical Cancer Research.

Expression of mutant p53 protein and CD44 variant proteins in colorectal tumorigenesis.

P. Herrlich, G. Offerhaus, G. Adolf, 1995, Gut.

Beyond Trastuzumab: Second-Generation Targeted Therapies for HER-2-positive Breast Cancer

M. Uttenreuther-Fischer, F. Solca, G. Adolf, 2011 .

CD44 splice variants: expression during lymphocyte activation and tumor progression.

P. Herrlich, K. Heider, A. Griffioen, 1993, Behring Institute Mitteilungen.

Immunoglobulin-producing hybrid cell lines, their use and method for their preparation

G. Bodo, G. Adolf, P. Swetly, 1984 .

Expression of CD44 isoforms in human skin cancer.

P. Herrlich, K. Heider, J. Simon, 1996, European journal of cancer.

5508 POSTER Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2, in models of head and neck cancer

H. Greulich, M. Krause, M. Baumann, 2007 .

The human lymphoma cell line NC-37: An alternative source of human lymphoblastoid interferon

G. Bodo, G. Adolf, P. Swetly, 1981 .

Abstract A208: Pharmacodynamic properties and antitumor efficacy of BI 836845, a fully human IGF ligand neutralizing antibody.

E. Ostermann, G. Adolf, H. Lamche, 2011 .

Molecular correlates of clinical benefit from antiangiogenic therapy for patients with lung adenocarcinoma: A hypothesis.

C. Haslinger, F. Hilberg, G. Adolf, 2014 .

567 POSTER Efficacy of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in combination with cytotoxic agents

A. Baum, F. Solca, F. Himmelsbach, 2006 .

BI 836845, a fully human IGF ligand neutralizing antibody, to improve the efficacy of rapamycin by blocking rapamycin-induced AKT activation.

K. Friedbichler, G. Adolf, T. Bogenrieder, 2012 .